Skip to main content

Table 3 Treatment toxicitya

From: A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma

Grade

1

2

3

4

5

N = 53

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

Neutropaenia

21 (39.6)

8 (15.0)

3 (5.6)

1 (1.8)

0

Thrombocytopaenia

9 (16.9)

4 (7.5)

1 (1.8)

0

0

Anaemia

21 (39.6)

8 (15.0)

0

1 (1.8)

0

Vomiting

9 (16.9)

3 (5.6)

1 (1.8)

0

0

Feverb

7 (13.2)

1 (1.8)

0

0

0

Fatigue

14 (26.4)

3 (5.6)

3 (5.6)

1 (1.8)

0

Alopecia

9 (16.9)

6 (11.3)

0

0

0

Hypoalbuminaemia

7 (13.2)

2 (3.7)

0

0

0

ALTc

9 (16.9)

3 (5.6)

1 (1.8)

0

0

Anorexia

16 (30.1)

11 (20.7)

1 (1.8)

0

0

Dermatitis radiation

10 (18.8)

5 (9.4)

1 (1.8)

0

0

Oesophagitis

25 (47.1)

16 (30.1)

5 (9.4)

0

0

Hypocalcaemia

6 (11.3)

2 (3.7)

0

0

0

Hypomagnesaemia

1 (1.8)

0

0

0

0

Hyponatraemia

2 (3.7)

0

2 (3.7)

0

0

Hypophosphataemia

3 (5.6)

0

0

0

0

Constipation

2 (3.7)

2 (3.7)

0

0

0

Diarrhea

3 (5.6)

0

0

0

0

Peripheral sensory neuropathy

13 (24.5)

4 (7.5)

0

0

0

Pneumonitis

5 (9.4)

0

1 (1.8)

0

2 (3.7)

Hypokalaemia

3 (5.6)

0

1 (1.8)

0

0

Hoarseness

5 (9.4)

0

0

0

0

Ventricular arrhythmia

1 (1.8)

0

0

0

0

Creatinine increased

1 (1.8)

0

0

0

0

Pericardial effusion

2 (3.7)

0

0

0

0

  1. aToxicity was grade according to the National Cancer Institute Common Toxicity Criteria, version 3.0; bOf the 8 patients, 3 patients experienced febrile neutropenia; CAlanine aminotransferase increased